MBRX (Moleculin Biotech) Total Assets: $23.36 Mil (As of Mar. 2026)

What is Moleculin Biotech Total Assets?

Moleculin Biotech MBRX +9.00% 30 Total Assets is $23.36 Mil as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Moleculin Biotech's Total Assets for the quarter that ended in Mar. 2026 was $23.36 Mil.

During the past 12 months, Moleculin Biotech's average Total Assets Growth Rate was 4.80% per year. During the past 3 years, the average Total Assets Growth Rate was -2.50% per year. During the past 5 years, the average Total Assets Growth Rate was -0.90% per year.

During the past 11 years, Moleculin Biotech's highest 3-Year average Total Assets Growth Rate was 8.40%. The lowest was -2.50%. And the median was 1.90%.

Total Assets is connected with ROA %. Moleculin Biotech's annualized ROA % for the quarter that ended in Mar. 2026 was -225.90%. Total Assets is also linked to Revenue through Asset Turnover. Moleculin Biotech's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Moleculin Biotech (NAS:MBRX) Total Assets Explanation

Total Assets is connected with ROA %.

Moleculin Biotech's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %	=	Net Income (Q: Mar. 2026 )	/	( (Total Assets (Q: Dec. 2025 )	+	Total Assets (Q: Mar. 2026 ))	/ count )
	=	-51.38	/	( (22.126	+	23.363)	/ 2 )
	=	-51.38	/	22.7445
	=	-225.90 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Moleculin Biotech's Asset Turnover for the quarter that ended in Mar. 2026 is

	Asset Turnover
=	Revenue (Q: Mar. 2026 )	/	( (Total Assets (Q: Dec. 2025 )	+	Total Assets (Q: Mar. 2026 ))	/ count )
=	0	/	( (22.126	+	23.363)	/ 2 )
=	0	/	22.7445
=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Moleculin Biotech Total Assets Related Terms

Moleculin Biotech Total Assets Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Total Assets can be seen below:

Moleculin Biotech Total Assets Chart

Moleculin Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Assets

Get a 7-Day Free Trial

84.09

57.42

38.22

16.93

22.13

Moleculin Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Assets	Get a 7-Day Free Trial															21.01	21.59	20.35	22.13	23.36

30GF Score

Moleculin Biotech Inc MBRX

Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Moleculin Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Moleculin Biotech's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets	=	Total Equity (A: Dec. 2025 )	+	Total Liabilities (A: Dec. 2025 )
	=	15.006	+	7.12
	=	22.13

Moleculin Biotech's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2026 )	+	Total Liabilities (Q: Mar. 2026 )
	=	15.183	+	8.18
	=	23.36

Frequently Asked Questions Learn more about Total Assets →

What does a Total Assets of $23.36 Mil mean?

Moleculin Biotech (MBRX) has a Total Assets of $23.36 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Moleculin Biotech and its competitors.

Is Moleculin Biotech's Total Assets too high?

Moleculin Biotech's current Total Assets is $23.36 Mil. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Moleculin Biotech's Total Assets compare to ICU and LEXX?

Moleculin Biotech's Total Assets of $23.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Assets for a Biotechnology company?

A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Assets mean?

A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Total Assets is $23.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Moleculin Biotech stock overvalued right now?

Moleculin Biotech (MBRX) has a current Total Assets of $23.36 Mil. The current Total Assets is $23.36 Mil. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Assets calculated?

Total Assets is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Total Assets is $23.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Industry Healthcare Biotechnology

Comparable Companies ICU LEXX INTI MTVA CVKD HCWB OSRH COCP HOOK LNAI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0K2H:UK

Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website https://www.moleculin.com

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

30GF Score

Get the complete analysis for MBRX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.26

Price

View MBRX Analysis

See Total Assets data for all stocks →